vivoVerse awarded SBIR Phase II grant from the NIEHS

vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $1.83M Phase II SBIR grant from the National Institute of Environmental Health Sciences (NIEHS) for the continued development of the company’s in vivo imaging and screening technologies. vivoVerse’s core focus is to facilitate the use of C. elegans as a model organism for life-science research Read more about vivoVerse awarded SBIR Phase II grant from the NIEHS[…]

vivoVerse cofounders publish single-cell isolation method using femtosecond laser microdissection (fs-LM)

vivoVerse cofounders Dr. Adela Ben-Yakar and Dr. Sudip Mondal have published an article in Nature Methods titled “Femtosecond laser microdissection for isolation of regenerating C. elegans neurons for single-cell RNA sequencing.” This publication from their work in the Ben-Yakar Group at the University of Texas at Austin showcases a novel and powerful fs-LM technique to isolate single cells from organisms or live mouse brain slices without Read more about vivoVerse cofounders publish single-cell isolation method using femtosecond laser microdissection (fs-LM)[…]

Meeting report: A successful and enjoyable time at SOT2023 in Nashville for vivoVerse

The vivoVerse team recently attended the 2023 Society of Toxicology (SOT) Annual Meeting. It was a great time networking with people in the toxicology and safety testing industry. At ToxExpo, we were happily busy at our booth (Figure 2) spreading the word about our toxicology screening services using the alternative animal model C. elegans as Read more about Meeting report: A successful and enjoyable time at SOT2023 in Nashville for vivoVerse[…]